Over 70% of breast cancers express the estrogen receptor (ER) and depend on ER 20 activity for survival and proliferation. While hormone therapies that target receptor activity are 21 initially effective, patients invariably develop resistance which is often associated with activation 22 of the PI3K/Akt/mTOR pathway. While the mechanism by which estrogen regulates proliferation 23
Introduction 37
Breast cancer is the most frequently diagnosed malignancy in women (1). Over 70% of 38 breast cancer patients are diagnosed with the estrogen receptor-positive (ER+) subtype, which 39 is characterized by the expression of the transcription factor ER and dependence on ER activity 40 for tumor cell growth and survival (2) (3) (4) (5) (6) . Patients diagnosed with the ER+ subtype of breast 41 cancer are typically prescribed endocrine therapies that target ER activity (2, 3, 6) . However, 42 resistance to endocrine therapies invariably occurs, leading to re-activation of the ER, 43 expression of ER-target genes, and ultimately, patient relapse (2, 3, 6) . Treatment options for 44 patients that are resistant to endocrine therapies are limited, highlighting the need for innovative 45 therapies that target downstream of the ER (2, 3, 6) . 46
Crosstalk between the ER and the PI3K/Akt/mTOR pathway has been implicated in ER+ 47 breast cancer progression and resistance to endocrine therapies (7) (8) (9) (10) . The PIK3CA gene, 48 which encodes the catalytic subunit of the PI3K enzyme, is the most commonly mutated gene in 49 ER+ breast cancer patients with over 40% incidence (11) . This mutation is speculated to be a 50 causal event in breast cancer progression, suggesting there is some need to upregulate this 51 pathway in the development of ER+ breast cancer (11). Studies have indicated the ER can 52 interact with PI3K to regulate its kinase activity in an estrogen-dependent manner (12). Further, 53 inhibition of the PI3K/Akt/mTOR pathway increases ER expression and sensitivity of breast 54 cancer cells to tamoxifen treatment, suggesting that activation of this pathway is associated with 55 resistance to endocrine therapies through downregulation of ER (13). Together, these data 56 indicate interdependence between ER and PI3K/Akt/mTOR signaling, however, the molecular 57 basis and clinical relevance for this cooperation remains unclear. 58
Herein, we show that the ER gene target, growth regulation by estrogen in breast cancer 1 59 (GREB1), is a regulator of the PI3K/Akt/mTOR pathway, linking ER activation to this critical 60 signaling pathway. Expression of GREB1 has been highly correlated to ER-positivity in breast 61 cancer cell lines and patient samples (14) (15) (16) (17) . Previous studies have shown that knockdown of 62 GREB1 results in significantly reduced proliferation and colony formation of ER+ breast cancer 63 cell lines indicating, a required role for GREB1 in regulation of estrogen-dependent proliferation 64 (16) (17) (18) . However, it appears that an optimal level of GREB1 expression is necessary for 65 proliferation of breast cancer cell lines as exogenous expression of GREB1 inhibits growth (18) . 66
Interestingly, growth repression by exogenous expression of GREB1 was also observed in ER-67 negative cell lines, indicating the ability of GREB1 to regulate proliferation of breast cancer cells 68 is independent of ER activity (18) . Despite the clear association of GREB1 and proliferation of 69 ER+ breast cancer, the molecular function of the protein and the mechanism by which it 70 regulates proliferation remain largely unknown. In this study, we characterize a novel 71 mechanism by which GREB1 regulates proliferation of ER+ breast cancer cell lines through 72 activation of Akt. 73
Materials and methods 74
Cell lines and reagents 75 MCF7, T47D, ZR-75-1, and HEK-293T cells were validated using Short Tandem Repeat 76 analysis by the Genomics Core in the Research Technology Support Facility (Michigan State 77 University, East Lansing, MI 48824). HCC1500 cells were purchased from the American Type 78 Culture Collection. Cells were maintained as previously described (18). For experiments with 79 EGF stimulation, cells were cultured in serum-free media for 16 hours before being stimulated 80 with 1 ng/mL recombinant human EGF (Thermo) for the indicated time. The inhibitors GDC-81 0941 was obtained from Cayman Chemicals and were used at the indicated concentration for 82 24 hours prior to harvest of the cells. 83
Plasmids 84
3XFLAG PCDNA and H2BGFP have been described previously (18) (19) (20) . GIPZ lentiviral 85 non-specific shRNA (# RHS4346) and lentiviral GREB1-targeted shRNA plasmids 86 (V2LHS_139192 and V3LHS_372339) were obtained from Open Biosystems. MISSION shRNA 87 constructs targeted to PIK3CA (TRCN0000196 582, TRCN0000195 203, TRCN0000010 406), 88 PTEN (TRCN0000002 745, TRCN0000002 747, TRCN0000002 749), and PDK1 89 (TRCN0000001 476, TRCN0000039 778, TRCN0000039 782, TRCN0000010 413) were 90 purchased from Sigma Aldrich. Myristoylated (Myr) AKT1 from pBabe-Puro-Myr-Flag-AKT1 (21) 91 was cloned into a pLenti-hygro backbone to create pLenti hygro Myr FLAG AKT1 (CA AKT) 92 using standard Gibson cloning (NEB). 93
Immunoblot analysis and antibodies 94
Cell lysates were prepared, subjected to immunoblot analysis, and visualized on a LI-95 COR Odyssey system as previously described (18, 22) . Immunoblots were probed with the 96 following antibodies: GREB1 (abcam; ab72999 or CST; P76195 Clone 9C1), β-actin (Cell 97
Signaling Technologies (CST); 3700), phosphor-p38 (CST; 9211S), p38 (CST; 9212), phosphor-98 MEK1/2 (CST; 9121), MEK1/2 (CST; 9122), phosphor-ERK1/2 (CST; 4370); ERK1/2 (CST; 99 4695), phospho-MKK3/6 (CST; 12280), phospho-MSK1 (CST; 9595), phospho-ATF2 (CST; 100 5112), phospho-HSP27 (CST; 9709), phospho-MAPKAPK2 (CST; 3007), phospho-PTEN (CST; 101 9551), PTEN (CST; 9556), phospho-PDK1 (CST; 3438), PDK1 (CST; 5662), phospho-Akt 102 Thr308 (CST; 13038), phospho-Akt Ser473 (CST; 9271S), Akt (CST; 2920S), PP2A (CST; 103 2041T), phospho-GSK3β (CST; 5558), mTOR (CST; 2983), Rictor (CST; 2114), Raptor (CST; 104 2280), and p110α (CST; 4249T). 105
Adenovirus 106
GREB1 adenovirus was purified as previously described (18) 
SA-β-gal staining 118
Cells transduced with GFP or GREB1 adenovirus were plated on poly-L-lysine coated 119 coverslips. Cells were fixed and stained for SA-β-gal activity using the Senescence β-120
Galactosidase Staining Kit (CST #9860) as previously described (23). 121
Conditioned media assay 122
MCF7 cells were transduced with either GFP or GREB1 adenovirus. After 24 hours, 123 transduced cells were washed in PBS and fresh media added. The following day, media was 124 collected from the transduced cells and centrifuged at 500 x g for 5 minutes to pellet any cellular 125 debris. Target cells were washed twice with PBS prior to the addition of conditioned media. After 126 24 hours, all cells were harvested by scraping in cold PBS containing 10 nM calyculin A (Cell 127
Signaling). 128
Co-culture assay 129
MCF7 cells were transduced with adenovirus expressing either GFP or GREB1 (both 130 adenovirus vectors express GFP). The following day, transduced cells were trypsinized and 131 replated at a 1:1 ratio with un-transduced MCF7 cells. Cells were harvested after 24 hours by 132 trypsinization and washed twice with cold PBS containing 10 nM calyculin A (Cell Signaling). 133
Cells were sorted from both the adGFP and adGREB1 co-cultures using a Becton Dickinson 134
FACSAria II cell sorter into GFP-positive (transduced) and GFP-negative (un-transduced) 135
populations. Cell lysates were prepared from the sorted populations and immunoblot analysis 136 was performed as described above. 137
Immunofluorescence microscopy 138
Cells were plated on poly-L-lysine-coated coverslips. Following treatment, cells were 139 fixed in 4% methanol-free formaldehyde (Thermo) diluted in PBS for 15 minutes at room 140 temperature. Cells were then washed three times in PBS before permeabilization with 0.5% 141 saponin, 1% BSA PBS solution at room temperature for 15 minutes. The cells were labeled with 142 the indicated primary antibodies for 2 hours at room temperature in a humidified chamber. 143
Coverslips were then washed three times in PBS before incubation with secondary antibodies 144 (Alexa Fluor 555 goat anti-mouse and Alexa Fluor 555 goat anti-rabbit; Invitrogen) at room 145 temperature for 1 hour in a humidified chamber, protected from light. Coverslips were mounted 146 on microscope slides with VECTASHIELD Hard Set Mounting Medium with DAPI (Vector 147 Laboratories). Images were obtained using a spinning disk confocal microscope (Ultra-VIEW 148
VoX CSU-X1 system; Perkin Elmer) and analyzed using Velocity (Perkin Elmer). 149 PIP 3 quantification 150 MCF7 cells were transduced with either GFP or GREB1 adenovirus. 24 hours after 151 transduction, cells were placed in serum-free, phenol-red-free DMEM for 16 hours. Lipids were 152 extracted and PIP 3 levels measured using the PIP 3 Mass ELISA kit (Echelon K-2500s) 153
according to the manufacturer's instructions. 154
Results 155
GREB1 initiates cellular senescence 156
Our previous work has suggested that an optimal level of GREB1 expression is 157 necessary for proliferation of breast cancer cell lines. This work showed that both GREB1 158 knockdown (18) and exogenous expression of GREB1 results in growth arrest ( Fig. 1A-B ) (18). 159
We previously reported that exogenous expression of GREB1 did not induce apoptosis (18), 160 thus we investigated the ability of GREB1 overexpression to initiate oncogene-induced cellular 161 senescence. Two ER+ breast cancer cell lines, MCF7 and ZR-75-1 cells, were transduced with 162 adenovirus expressing either GFP or GREB1. Following 7 days of exogenous GREB1 163 expression, the cells were fixed and stained for SA-β-galactosidase activity, a marker of cellular 164 senescence (23, 24). Compared to GFP control cells, cells overexpressing GREB1 had a large, 165 flattened morphology and characteristic blue staining associated with SA-β-galactosidase 166 activity (Fig. 1C ). These data suggest that exogenous GREB1 expression is able to induce 167 cellular senescence to inhibit proliferation of breast cancer cell lines. 168
Exogenous GREB1 expression induces hyperactivation of the PI3K/Akt/mTOR pathway 169
In order to delineate the mechanism by which GREB1 regulates proliferation, we chose 170 to focus our attention on two signaling pathways thought to play a critical role in regulating both 171 senescence and proliferation phenotypes: the p38 MAPK pathway and the PI3K/Akt/mTOR 172 pathway (25-27). MCF7 cells were transduced with adenovirus expressing GFP or GREB1 and 173 after 48 hours, cell lysates were analyzed by immunoblot for activation of various nodes in the 174 p38 MAPK pathway ( Fig. 2A ) and the PI3K/Akt/mTOR pathway ( Fig. 2B ). Our data indicate that 175 exogenous GREB1 expression induces an increase in the activation and phosphorylation of p38 176 and its downstream effector, MAPKAPK2, however, the activation and/or expression of 177 upstream regulators of p38 (MEK1/2, ERK1/2, MKK3/6) and other downstream effectors (MSK1, 178 ATF2, and HSP27) were largely unaffected ( Fig. 2A ). Analysis of the PI3K/Akt/mTOR pathway 179 revealed hyperactivation of Akt, as well as increased phosphorylation of GSK3β, a downstream 180 effector of Akt, when GREB1 was exogenously expressed in MCF7 cells (Fig. 2B ). As the 181 PI3K/Akt/mTOR pathway is frequently altered in breast cancer, we analyzed the effect of 182 GREB1 overexpression on Akt activation in a panel of ER+ breast cancer cell lines with wildtype 183 or differing alterations to the PI3K/Akt/mTOR pathway (28). While MCF7, ZR-75-1, and T47D 184 cells harbor mutations in this pathway, each cell line has varying levels of Akt activation with 185 MCF7 cells demonstrating the least constitutive activity (Supplemental Fig. 1 ). In cells lines 186 without constitutive maximal activity of this pathway, GREB1 induces a strong activation of Akt 187 ( Fig. 2C ). In contrast, T47D cells, which have a PIK3CA mutation resulting in constitutively 188
active Akt that does not respond to serum deprivation (Supplemental Fig. 1 ), are unaffected by 189 GREB1 expression ( Fig. 2C) . 190
GREB1-induced hyperactivation of Akt is PI3K-dependent 191
Akt requires phosphorylation at two sites, Thr308 and Ser473, by PDK1 and mTORC2 192 respectively, for maximal activation (29-31). Both phosphorylation events are dependent on 193 PI3K and occur downstream of PI3K conversion of PIP 2 to PIP 3 (29, 31). Thus, we sought to 194 determine if GREB1 was acting to regulate Akt activation upstream or downstream of PI3K. To 195 this end, we targeted PI3K activity with the pharmaceutical inhibitor GDC0941. MCF7 cells were 196 simultaneously treated with DMSO or GDC0941 and transduced with adenovirus expressing 197 GFP or GREB1. After 24 hours, cell lysates were harvested and activation of Akt at Thr308 and 198 Ser473 were evaluated by immunoblot analysis. The expected hyperactivation of Akt was 199 observed in DMSO-treated cells that were transduced with GREB1 adenovirus (Fig. 3A ). PI3K 200 inhibition by GDC0941 demonstrated a marked decrease in basal Akt activation in the control 201 GFP-transduced cells (Fig. 3A) . A decrease in GREB1-mediated activation was also observed, 202 particularly at Ser473 (Fig. 3A ), suggesting that GREB1 is activating the canonical PI3K/Akt 203
axis. 204
To confirm this result and further probe other nodes in the pathway, MCF7 cells were 205 transduced with lentivirus expressing shRNA targeted to a non-specific control (shNS), PIK3CA, 206 PTEN, or PDK1. Following selection, cells were transduced with adenovirus expressing GFP or 207 GREB1. After 24 hours, cell lysates were harvested and analyzed via immunoblot. Control cells 208 transduced with non-specific shRNA demonstrated the expected increase in phosphorylation of 209
Akt (Thr308 and Ser473) and GSK3β when GREB1 was exogenously expressed (Fig. 3B) . 210
Knockdown of PIK3CA expression reduced Akt activation in both control and GREB1-211 expressing cells (Fig. 3B ). GREB1-induced hyper-phosphorylation of GSK3β was also reduced 212 when PIK3CA was knocked-down ( Fig. 3B ). Knockdown of PTEN enhanced GREB1-induced 213 hyperactivation of Akt at Thr308, suggesting the mechanism of GREB1 action is not through 214 phosphatase inhibition (Fig. 3B) . In contrast to our pharmacological approach (Fig. 2B ), GREB1-215 induced hyperactivation of Akt at Thr308 was completely blocked by knockdown of PDK1, the 216 primary kinase for this site (29-32)( Fig. 3B ). As expected, PDK1 knockdown had no effect on 217 GREB1-induced hyperactivation of Akt at Ser473, as this is not the primary kinase for this site 218 (29-31) ( Fig. 3B ). Knockdown of PDK1 diminished GREB1-induced phosphorylation of GSK3β 219 ( Fig. 3B) . These data further demonstrate that GREB1-induced hyperactivation of Akt is 220 dependent on signaling through the canonical PI3K pathway. 221
GREB1 activates Akt through intracellular mechanisms 222
Canonical activation of PI3K and Akt occurs through activation of receptor tyrosine 223 kinases (RTK) or G-protein-coupled receptors (GPCR) by external stimuli (29, 33) . We first 224 sought to determine if GREB1-mediated Akt regulation is dependent upon induction and 225 secretion of a signaling molecule that activates the PI3K/Akt/mTOR pathway. To this end, MCF7 226 cells were transduced with adenovirus expressing GFP or GREB1. Media from transduced cells 227 was transferred to un-transduced MCF7 cells. After 24 hours, cell lysates were harvested and 228 activation of Akt was analyzed by immunoblot. As expected, exogenous expression of GREB1 229 induced hyperactivation of Akt at Ser473 when compared to GFP-transduced cells (Fig, 4A) . 230
However, conditioned media was unable to induce hyperactivation of Akt in un-transduced cells 231 ( Fig. 4A) . 232
Alternatively, exogenous GREB1 may induce the expression of a membrane-bound 233 signaling molecule that could activate the PI3K/Akt/mTOR pathway. To investigate this 234 possibility, MCF7 cells were transduced with adenovirus expressing GFP or GREB1 and then 235 co-cultured at a 1:1 ratio with un-transduced MCF7 cells. After 24 hours, the cells were 236 harvested and GFP-positive, adenovirus-transduced cells (GFP or GREB1), were sorted from 237 GFP-negative, un-transduced cells. All populations were then analyzed for activation of Akt by 238 immunoblot. Both GFP-transduced cells and cells co-cultured with the GFP-transduced cells 239 had similar levels of Akt activation (Fig. 4B ). Exogenous expression of GREB1 induced the 240 expected hyperactivation of Akt at Ser473 within the transduced cells; however, the un-241 transduced co-culture cells did not demonstrate Akt hyperactivation (Fig. 4B ). While these data 242 are negative, they clearly demonstrate that GREB1 regulates Akt activation through in an 243 intracellular mechanism that does not require extracellular activation of RTKs. 244
Exogenous GREB1 promotes recruitment of Akt to the plasma membrane 245
Akt is typically activated via recruitment to the plasma membrane by interaction with 246 PIP 3 , however, it is believed that there are other pools of activated Akt on endomembrane 247 surfaces and within the nucleus (29). To determine the localization of activated Akt induced by 248 exogenous GREB1 expression, MCF7 cells were transduced with either GFP or GREB1 249 adenovirus. Following transduction, the cells were serum-starved for 16 hours to reduce basal 250
Akt activation before stimulation of the pathway with EGF. Cells were then fixed and stained 251 with DAPI and the indicated Akt antibodies. As both adenoviral vectors expressed GFP, we 252 focused our imaging on transduced cell populations. In serum-starved, GFP-transduced cells, 253 staining for activated Akt was minimal and staining for total Akt resulted in diffuse staining 254 throughout the cytoplasm (Fig. 5A, Supplemental Fig. 2A-B) . In contrast, cells transduced with 255 GREB1 adenovirus under serum-starved conditions had distinct staining for activated and total 256
Akt, primarily localized to the plasma membrane ( Fig. 5A, Supplemental Fig. 2A-B) . When 257 stimulated with EGF for 5 minutes, both GFP-and GREB1-transduced cells demonstrated 258 activated Akt and total Akt at the plasma membrane ( Fig. 5A, Supplemental Fig. 2A-B) . 259
Activation of Akt and focal localization of total Akt at the plasma membrane was noticeably 260 stronger in GREB1-transduced cells when compared to GFP-transduced cells in the presence 261 of EGF (Fig. 5A, Supplemental Fig. 2A-B) . These data further suggest that GREB1 may act 262 through PI3K to increase PIP 3 levels and Akt re-localization to the plasma membrane. 263
We sought to directly test if GREB1 expression influenced the conversion of PIP 2 to 264 PIP 3 . MCF7 cells were transduced with GFP and GREB1 adenovirus and then placed in serum-265 free media as depicted in Figure 5A . Following serum starvation for 16 hours, lipids were 266 extracted and PIP 3 levels measured by ELISA. Expression of exogenous GREB1 induced a 267 significant increase in PIP 3 levels, further indicating that GREB1 augments PI3K activity. 268
Previous studies have suggested that GREB1 is primarily localized to the nucleus in 269 patient samples and breast cancer cell lines (15, 16), thus, it remained unclear how GREB1 was 270 able to regulate signaling through a primarily cytoplasmic pathway. Interestingly, we discovered 271 that under serum-starved conditions, endogenous GREB1 is diffuse throughout the cytoplasm 272 and nucleus in MCF7 cells, but upon stimulation with EGF, the vast majority of GREB1 rapidly 273 re-localizes to the cytoplasm (Supplemental Fig. 3A ). As this is contradictory to previously 274 published reports, we performed nuclear/cytoplasmic fractionation to verify cytoplasmic 275 expression of GREB1. Under normal growth conditions (i.e. media containing FBS), GREB1 is 276 primarily located within the cytoplasm of MCF7 cells (Supplemental Fig. 3B-C) . Thus, in 277 response to growth factor activation, GREB1 localizes to the cytoplasm wherein it can modulate 278 the PI3K pathway. 279
GREB1 regulates breast cancer proliferation through activation of the PI3K/Akt/mTOR 280 pathway 281
In order to determine if GREB1-mediated Akt activation is imperative for proliferation of 282 ER+ breast cancer cells, we tested whether constitutively activated Akt can rescue proliferation 283 loss in GREB1 depleted cells. Thus, we made use of T47D cells which are ER+ and GREB1-284 expressing, but harbor a PI3KCA H1047L mutation rendering this pathway constitutively active and 285 unresponsive to typical PI3K/Akt/mTOR-activating stimuli, including GREB1 exogenous 286 expression ( Fig. 2C and Supplemental Fig. 1 ). T47D cells were transduced with shRNA 287 targeting a nonspecific control (shNS) or shRNA targeting GREB1 (shGREB1 #1 or shGREB1 288 #2). Immunoblot analysis confirmed knockdown of GREB1, as well as hyperactivation of Akt in 289 T47D cells (Fig. 6A ). Proliferation of these cells was then monitored via alamar blue assay. 290 GREB1 knockdown had no effect on the proliferation of T47D cells (Fig. 6B ), suggesting 291 constitutive Akt activation abrogates the need for GREB1 expression. 292
The proliferation of ER+ and GREB1-expressing MCF7 cells has previously been shown 293 to be dependent on expression of GREB1 (16) (17) (18) . While MCF7 cells also harbor a mutation in 294 PIK3CA E545K , which is thought to be an activating mutation (34), these cells are still responsive 295 to typical PI3K/Akt/mTOR-activating stimuli (Supplemental Fig. 1) . Thus, we sought to 296 determine if constitutively activated Akt (myristoylated-Akt) would rescue proliferation in 297 GREB1-depleted MCF7 cells. MCF7 cells were transduced with empty vector lentivirus (EV) or 298 lentivirus expressing constitutively activated Akt (CA AKT) in combination with lentivirus 299 expressing shRNA targeted to a non-specific control (shNS) or to GREB1 (shGREB1 #1 or 300 shGREB1 #2). Knockdown of endogenous GREB1 resulted in decreased Akt activation in cells 301 co-transduced with GREB1-targeted shRNA and empty vector lentivirus (Fig. 6C) as well as 302 parental cells infected with control lentivirus (Supplemental Fig. 4) . The knockdown of GREB1 303 significantly impaired the growth of MCF7 cells co-transduced with empty vector lentivirus (Fig.  304   6D) . However, expression of constitutively active Akt (Fig. 6E) , rescues the proliferation 305 phenotype caused by GREB1 knockdown to that of control transduced cells (Fig. 6F) . Together, 306 these data demonstrate that the primary mechanism by which GREB1 drives estrogen-307 dependent proliferation is through modulation of Akt activity. Interestingly, stable expression of 308 constitutively active Akt results in long-term silencing of GREB1 (Supplemental Fig. 5) , 309 suggesting a feedback loop and potentially explaining the observation that GREB1 expression is 310 reduced in hormone-refractory disease {Mohammed, 2013 #169}. 311
Discussion 312
Despite extensive research on hormone signaling in breast cancer, the explicit 313 mechanism by which ER drives proliferation remains largely undefined. In order to delineate this 314 mechanism, concerted efforts have been made to identify ER-target genes involved in estrogen-315 induced proliferation of breast cancer cells. Several of these studies have identified GREB1 as a 316 gene that is required for estrogen-stimulated proliferation of breast cancer cell lines (14, 16, 17) . 317
Previous studies have suggested that GREB1 regulates proliferation through modulation of ER 318 activity (16). However, our findings show that GREB1 is not a potent regulator of ER activity and 319 has the ability to affect the proliferation of breast cancer cell lines independent of ER expression 320 and action (18). Here, we suggest a novel mechanism by which GREB1 regulates proliferation 321 through fine-tuning of PI3K/Akt/mTOR signaling. 322
GREB1 regulates proliferation of ER+ breast cancer cells through modulation of Akt 323 activity 324
Several studies have indicated complex crosstalk between ER signaling and 325 PI3K/Akt/mTOR pathway activation and implications for this crosstalk in resistance to endocrine 326 therapy in breast cancer patients (7) (8) (9) (35) (36) (37) . However, no studies have described a 327 comprehensive connection between activation of these signaling pathways and proliferation of 328 breast cancer cells. The difficulty to assess this connection is compounded by the fact that the 329 vast majority of available breast cancer cell lines contain mutations involved in the 330 PI3K/Akt/mTOR pathway (38) . Although most ER+ breast cancer cell lines contain mutations 331 within this pathway, the specific mutations have distinctly different effects on the activation of 332 the PI3K/Akt/mTOR pathway. Specifically, breast cancer cell lines harboring PIK3CA H1047R 333 mutations (ex. T47D) have significantly higher intrinsic PI3K activity compared to breast cancer 334 cell lines harboring PIK3CA E545K mutations (ex. MCF7), which have subtle effects on activation of 335 the PI3K/Akt/mTOR pathway (11, 39) . Using this to our advantage we show that in T47D cells, 336 which harbor a constitutively active PI3K/Akt/mTOR pathway, GREB1 is no longer required for 337 proliferation (Fig. 6A-B ). However, in MCF7 cells, which harbor a PIK3CA mutation but still 338 respond to pathway-activating stimuli, GREB1 is still required but knockdown of GREB1 can be 339 rescued by constitutively active Akt (Fig. 6C-F) . These data demonstrate that the requirement of 340 GREB1 for hormone-responsive proliferation is dependent upon this novel function to alter Akt 341 activity. Furthermore, the activation of the PI3K/Akt by GREB1 occurs through intracellular 342 mechainisms (Fig. 4) , highlighting a potentially new mode of modulating this signaling pathway 343 without the need for RTK activation. 344
GREB1 and endocrine resistance 345
Despite the clear association between GREB1 and proliferation of breast cancer cells, 346 expression of GREB1 has been correlated to better prognosis in ER+ breast cancer patients 347 (16, 40) . In a study that included only patients that received adjuvant tamoxifen monotherapy, 348 higher GREB1 expression correlated with both prolonged disease-free survival and sensitivity to 349 tamoxifen treatment (40) . Similarly, in an in vitro model of tamoxifen resistance, MCF7 cells that 350 were resistant to tamoxifen treatment had significantly less GREB1 expression compared to the 351 parental line, suggesting GREB1 expression is lost in hormone-refractory breast cancer cells 352 (16). These data have implicated loss of GREB1 as a causal event for therapy-resistance. Here, 353
we show that proliferation of breast cancer cells with constitutively active PI3K/Akt/mTOR 354 signaling no longer require GREB1 expression ( Fig. 6 ). Constitutive activation of the 355 PI3K/Akt/mTOR pathway is frequently associated with resistance to endocrine therapies and is 356 the basis for numerous clinical trials investigating PI3K/Akt/mTOR pathway inhibitors in 357 endocrine-resistant patient populations (7) (8) (9) (10) . In patients with hormone-refractory disease with 358 hyperactivation of the PI3K/Akt/mTOR pathway, the pressure to express GREB1 is lost. Thus, 359 decreased GREB1 expression in advanced disease may be the result of constitutive 360 PI3K/Akt/mTOR activity rather than a cause of therapeutic bypass. In support of this notion, 361 stable expression of constitutively active Akt resulted in silencing of GREB1 expression after 362 several passages (Supplemental Fig. 5 ). These findings warrant further research into the use of 363 GREB1 as a clinical biomarker for treatment selection. 364
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We thank Paul Herman, Clarissa Wormsbaecher, Weiwei Liu, and Makanko Komara for critical 370 reading of this manuscript prior to submission. 371 were then cultured with un-transduced cells at a 1:1 ratio for 24 hours. Cells were harvested and sorted for 526 GFP. Cell lysates were analyzed via immunoblot for expression of the indicated proteins. 527 were transduced with adenovirus expressing GFP or GREB1. The cells were then cultured in serum-free 529 media for 16 hours before being stimulated with 1 ng/mL EGF for 0 or 5 minutes. Cells were fixed and 530 stained for DAPI or p-Akt (Ser473). Immunofluorescence microscopy was used to visualize the activation 531 and localization of Akt. B) MCF7 cells were transduced with adenovirus to express exogenous GFP or 532 GREB1 and serum starved for 16 hours. Lipids were extracted from all samples and levels of PIP 3 were 533 measured via ELISA. Graphs represent mean PIP 3 (pmol) + SD (n=3). 534
Figure 6-GREB1 regulates breast cancer proliferation through activation of the PI3K/Akt pathway 535
A) T47D cells were transduced with lentivirus expressing non-specific shRNA or shRNA targeted to 536 GREB1 (shGREB1 #1 or shGREB1 #2). Immunoblot depicting the expression of indicated proteins. B) 537
Proliferation was measured via alamar blue assay. Data are plotted as mean fluorescence normalized to 538 Day 0 ± SD; n=3. C) MCF7 cells were transduced with lentivirus expressing empty vector (EV) and 539 either non-specific shRNA or shRNA targeted to GREB1 (shGREB1 #1 or shGREB1 #2). Immunoblot 540 showing the expression of labeled proteins. D) Proliferation was measured via almar blue assay. Data are 541 plotted as mean fluorescence normalized to Day 0 ± SD; n=3. E) MCF7 cells were transduced with 542 lentivirus expressing myristoylated Akt (CA AKT) and either non-specific shRNA or shRNA targeted to 543 GREB1 (shGREB1 #1 or shGREB1 #2). Immunoblot demonstrating the expression of indicated protein. then cultured in serum-free media for 16 hours before being stimulated with 1 ng/mL EGF for 0 or 5 553 minutes. Cells were fixed and stained for DAPI and A) Akt or B) p-Akt (Thr308). Immunofluorescence 554 microscopy was used to visualize the activation and localization of Akt. 555
Supplemental Figure S3 Endogenous GREB1 re-localizes to the cytoplasm under growth-556 stimulatory conditions. A) MCF7 cells were serum starved for 4 hours and stimulated with 1 ng/mL 557 EGF for 0, 5, or 15 minutes. Cells were fixed and stained for DAPI and endogenous GREB1. 558
Immunofluorescence microscopy was used to visualize GREB1 localization. B) Cytoplasmic and nuclear 559 fractions were extracted from MCF7 whole cell lysate using high-speed centrifugation. Fractionated cell 560 lysates were subjected to SDS-PAGE and analyzed via immunoblot for indicated proteins. C) MCF7 cells 561 cultured in full serum media were fixed and stained for DAPI and endogenous GREB1. 562
Immunofluorescence microscopy was used to visualize GREB1 localization under normal growth 563 conditions. 564
Supplemental Figure S4 Endogenous GREB1 regulates Akt activation MCF7 cells transduced with 565
lentivirus expressing non-specific shRNA (shNS) or one of two shRNAs targeted to GREB1 (shGREB1 566 #1 or shGREB1 #2) were placed in serum/phenol red free media for 16 hours followed by 1 hour of 567 activation with 1ng/ml EGF. Cells were harvested and lysates analyzed via immunoblot for Akt activation 568 
